vs

Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and XCel Brands, Inc. (XELB). Click either name above to swap in a different company.

XCel Brands, Inc. is the larger business by last-quarter revenue ($1.2M vs $838.0K, roughly 1.4× Prime Medicine, Inc.). XCel Brands, Inc. runs the higher net margin — -237.8% vs -5498.7%, a 5260.9% gap on every dollar of revenue. On growth, XCel Brands, Inc. posted the faster year-over-year revenue change (-3.4% vs -61.6%). XCel Brands, Inc. produced more free cash flow last quarter ($-7.0M vs $-37.5M).

Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.

XCel Brands, Inc. is a consumer goods and brand management firm that owns, licenses, and markets lifestyle brands spanning apparel, accessories, and home products. It operates mainly in North America, partnering with leading retail chains to distribute products to mass and mid-tier consumer segments.

PRME vs XELB — Head-to-Head

Bigger by revenue
XELB
XELB
1.4× larger
XELB
$1.2M
$838.0K
PRME
Growing faster (revenue YoY)
XELB
XELB
+58.2% gap
XELB
-3.4%
-61.6%
PRME
Higher net margin
XELB
XELB
5260.9% more per $
XELB
-237.8%
-5498.7%
PRME
More free cash flow
XELB
XELB
$30.5M more FCF
XELB
$-7.0M
$-37.5M
PRME

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PRME
PRME
XELB
XELB
Revenue
$838.0K
$1.2M
Net Profit
$-46.1M
$-2.8M
Gross Margin
Operating Margin
-5800.5%
-166.8%
Net Margin
-5498.7%
-237.8%
Revenue YoY
-61.6%
-3.4%
Net Profit YoY
-9.0%
60.8%
EPS (diluted)
$-0.22
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRME
PRME
XELB
XELB
Q4 25
$838.0K
$1.2M
Q3 25
$1.2M
$1.1M
Q2 25
$1.1M
$1.3M
Q1 25
$1.5M
$1.3M
Q4 24
$2.2M
$1.2M
Q3 24
$1.9M
Q2 24
$0
$3.0M
Q1 24
$591.0K
$2.2M
Net Profit
PRME
PRME
XELB
XELB
Q4 25
$-46.1M
$-2.8M
Q3 25
$-50.6M
$-7.9M
Q2 25
$-52.6M
$-4.0M
Q1 25
$-51.9M
$-2.8M
Q4 24
$-42.3M
$-7.1M
Q3 24
$-9.2M
Q2 24
$-55.3M
$195.0K
Q1 24
$-45.8M
$-6.3M
Gross Margin
PRME
PRME
XELB
XELB
Q4 25
Q3 25
100.0%
Q2 25
100.0%
Q1 25
Q4 24
100.0%
Q3 24
78.7%
Q2 24
98.7%
Q1 24
100.0%
Operating Margin
PRME
PRME
XELB
XELB
Q4 25
-5800.5%
-166.8%
Q3 25
-4406.0%
-665.7%
Q2 25
-4787.2%
-125.2%
Q1 25
-3603.3%
-164.2%
Q4 24
-2025.7%
-532.9%
Q3 24
-474.8%
Q2 24
10.4%
Q1 24
-8179.5%
-283.7%
Net Margin
PRME
PRME
XELB
XELB
Q4 25
-5498.7%
-237.8%
Q3 25
-4129.1%
-706.5%
Q2 25
-4716.7%
-301.9%
Q1 25
-3568.8%
-210.0%
Q4 24
-1936.6%
-585.9%
Q3 24
-481.9%
Q2 24
6.6%
Q1 24
-7743.0%
-288.2%
EPS (diluted)
PRME
PRME
XELB
XELB
Q4 25
$-0.22
$-0.22
Q3 25
$-0.32
$-2.02
Q2 25
$-0.41
$-1.66
Q1 25
$-0.40
$-1.18
Q4 24
$-0.31
$-2.91
Q3 24
$-3.92
Q2 24
$-0.46
$0.08
Q1 24
$-0.44
$-3.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRME
PRME
XELB
XELB
Cash + ST InvestmentsLiquidity on hand
$63.0M
$1.1M
Total DebtLower is stronger
$12.7M
Stockholders' EquityBook value
$120.9M
$18.0M
Total Assets
$342.7M
$38.9M
Debt / EquityLower = less leverage
0.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRME
PRME
XELB
XELB
Q4 25
$63.0M
$1.1M
Q3 25
$71.4M
$1.5M
Q2 25
$53.8M
$970.0K
Q1 25
$91.9M
$298.0K
Q4 24
$182.5M
$1.3M
Q3 24
$242.0K
Q2 24
$55.6M
$924.0K
Q1 24
$94.2M
$1.6M
Total Debt
PRME
PRME
XELB
XELB
Q4 25
$12.7M
Q3 25
$12.5M
Q2 25
$12.3M
Q1 25
$8.7M
Q4 24
$6.6M
Q3 24
$4.3M
Q2 24
$4.5M
Q1 24
$4.7M
Stockholders' Equity
PRME
PRME
XELB
XELB
Q4 25
$120.9M
$18.0M
Q3 25
$161.8M
$18.7M
Q2 25
$60.9M
$24.5M
Q1 25
$106.9M
$27.7M
Q4 24
$153.1M
$30.4M
Q3 24
$36.9M
Q2 24
$196.6M
$46.0M
Q1 24
$243.8M
$45.8M
Total Assets
PRME
PRME
XELB
XELB
Q4 25
$342.7M
$38.9M
Q3 25
$385.0M
$40.5M
Q2 25
$279.0M
$47.2M
Q1 25
$328.2M
$52.5M
Q4 24
$297.5M
$53.8M
Q3 24
$54.0M
Q2 24
$259.7M
$63.2M
Q1 24
$311.4M
$66.8M
Debt / Equity
PRME
PRME
XELB
XELB
Q4 25
0.71×
Q3 25
0.67×
Q2 25
0.50×
Q1 25
0.31×
Q4 24
0.22×
Q3 24
0.12×
Q2 24
0.10×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRME
PRME
XELB
XELB
Operating Cash FlowLast quarter
$-37.3M
$-7.0M
Free Cash FlowOCF − Capex
$-37.5M
$-7.0M
FCF MarginFCF / Revenue
-4480.4%
-602.1%
Capex IntensityCapex / Revenue
34.6%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-167.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRME
PRME
XELB
XELB
Q4 25
$-37.3M
$-7.0M
Q3 25
$-35.0M
$-1.4M
Q2 25
$-41.4M
$-2.4M
Q1 25
$-48.9M
$-1.4M
Q4 24
$16.2M
$-4.7M
Q3 24
$-424.0K
Q2 24
$-45.5M
$-274.0K
Q1 24
$-67.7M
$-2.6M
Free Cash Flow
PRME
PRME
XELB
XELB
Q4 25
$-37.5M
$-7.0M
Q3 25
$-35.3M
Q2 25
$-43.0M
$-2.4M
Q1 25
$-51.3M
$-1.4M
Q4 24
$14.5M
$-4.8M
Q3 24
$-432.0K
Q2 24
$-47.4M
Q1 24
$-70.0M
FCF Margin
PRME
PRME
XELB
XELB
Q4 25
-4480.4%
-602.1%
Q3 25
-2880.5%
Q2 25
-3855.1%
-179.3%
Q1 25
-3526.8%
-108.7%
Q4 24
662.1%
-399.3%
Q3 24
-22.6%
Q2 24
Q1 24
-11849.6%
Capex Intensity
PRME
PRME
XELB
XELB
Q4 25
34.6%
0.9%
Q3 25
20.2%
0.0%
Q2 25
141.0%
0.3%
Q1 25
166.6%
1.1%
Q4 24
82.0%
9.3%
Q3 24
0.4%
Q2 24
Q1 24
393.2%
Cash Conversion
PRME
PRME
XELB
XELB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-1.41×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons